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Aim To analyze the trends of pancreatic cancer mortality 
in Serbia.
Methods The study covered the population of Serbia in 
the period 1991 to 2010. Mortality trends were assessed by 
the joinpoint regression analysis by age and sex.
Results Age-standardized mortality rates ranged from 
5.93 to 8.57 per 100 000 in men and from 3.51 to 5.79 per 
100 000 in women. Pancreatic cancer mortality in all age 
groups was higher among men than among women. It 
was continuously increasing since 1991 by 1.6% (95% con-
fidence interval [CI] 1.1 to 2.0) yearly in men and by 2.2% 
(95% CI 1.7 to 2.7) yearly in women. Changes in mortality 
were not significant in younger age groups for both sex-
es. In older men (≥55 years), mortality was increasing, al-
though in age groups 70-74 and 80-84 the increase was 
not significant. In 65-69 years old men, the increase in 
mortality was significant only in the period 2004 to 2010. 
In ≥50 years old women, mortality significantly increased 
from 1991 onward. In 75-79 years old women, a non-signif-
icant decrease in the period 1991 to 2000 was followed by 
a significant increase from 2000 to 2010.
Conclusion Serbia is one of the countries with the highest 
pancreatic cancer mortality in the world, with increasing 
mortality trend in both sexes and in most age groups.
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According to the GLOBOCAN 2008 estimates, pancreat-
ic cancer causes more than 270 000 deaths per year (ac-
counts for 3.5% of all deaths), ranking ninth among the 
leading causes of cancer death in both sexes together 
(1-3). It is one of the most lethal malignant neoplasms, with 
the 5-year survival rate of less than 5% (4,5).
The majority of pancreas cancer deaths (61%) occurs in de-
veloped countries, where pancreatic cancer is the fifth lead-
ing cause of death in men and the fourth in women (1,3,4). 
The highest mortality rates of pancreatic cancer are report-
ed in North America (6.9 per 100 000) and Europe (from 6.6 
per 100 000 in western Europe to 5.9 in southern Europe) 
and the lowest in less developed countries in South Asia 
and Central Africa (approximately 1.5 per 100 000) (3).
Pancreatic cancer is more common in men than women – 
in 2008, age-adjusted worldwide mortality rates were 4.2 
per 100 000 in men and 3.1 per 100 000 in women (3,4). It is 
predominantly a disease of the elderly, and almost 90% of 
all cases are diagnosed after the age of 55 years (3). In Ser-
bia in 2008, pancreatic cancer was the fifth most common 
cause of cancer mortality in both sexes, with death rates 
similar to those in developed countries (8.3 per 100 000 in 
men and 5.5 in women) (3).
In the recent decade, pancreatic cancer mortality in devel-
oped countries has been increasing (for example, in the 
USA by 0.5% per year for both sexes; in Japan by 0.6%, but 
only in women; in the European Union, also only in wom-
en) (6-8). Since there are no corresponding data for the Ser-
bian population, the aim of the present study was to ana-




Data on individuals who died of pancreatic cancer (code 157 
revision 9 of the International Classification of Diseases from 
1991 to 1996, and code C25 revision 10 from 1997) (9,10) 
were obtained from the Statistical Office of the Republic of 
Serbia (unpublished data). All deaths occurring in Serbia are 
registered in death files (certificate of death and a special 
statistical form – DEM 2) (11). A death certificate is obtained 
from an authorized physician in a health care organization, 
a coroner, or a forensic physician. Death files are checked 
by the local registrar and forwarded to the referral public 
health institute, where they are checked again and if 
necessary corrected by another trained medical doctor or 
specialist. The research included the entire population of 
Serbia in the period 1991 to 2010, excluding the Autono-
mous Province of Kosovo and Metohia, for which data have 
been unavailable since 1998. Data on the number and dis-
tribution according to sex and age were obtained from the 
population censuses in 1991 and 2002 (12). For inter-cen-
sus years, the estimates published by the Statistical Office 
of the Republic of Serbia were used (12). Data for internally 
displaced persons and refugees were included in the popu-
lation of Serbia and could not have been regarded as a spe-
cial contingent.
Statistical analysis
Three types of death rates were calculated: crude, age-spe-
cific, and age-standardized calculated by the direct meth-
od from the world standard population (13) and expressed 
as deaths per 100 000 persons stratified by sex. Age-spe-
cific rates were computed for 5-year age groups. Rates are 
not presented for the age subgroups (<40 years) with few-
er than five pancreatic cancer deaths in any year in each of 
the quinquenniums.
Pancreatic cancer mortality trends were assessed by join-
point regression analysis (Joinpoint Regression software, ver-
sion 3.5.3, available through the Surveillance Research Pro-
gram of the US National Cancer Institute). The significance 
level was set at P ≤ 0.05. Each joinpoint marks a significant 
change in the trend, and an annual percentage of change 
(APC) and the corresponding 95% confidence interval are 
computed from each trend using generalized linear models 
assuming a Poisson distribution (14). In the final model, the 
joinpoint analysis also provides an average annual percent-
age change (AAPC) – a summary measure over a fixed inter-
val, which is computed as a weighted average of the APCs 
from the joinpoint model. We used age-standardized rate as 
the dependent variable and year as the independent vari-
able. The by-variables were sex and age group. A number of 
joinpoints was set between 0 and 4. Grid Search method was 
selected (15). The minimum number of data points from the 
beginning of the series was set at 5 and there were at least 
4 data points between two joinpoints. The permutation test 
was used to select the best joinpoint models with overall sig-
nificance level of 0.05 and 4499 randomly selected data sets 
(16). We used a specific procedure – comparability test to 
compare two segmented line regression functions. All two-
way combinations of the sex and age groups by variable 
were tested. The main goal of the comparability test was to 
compare two sets of trend data whose mean functions are 
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represented by joinpoint regression. Specific interests were 
to test (i) whether two joinpoint regression functions were 
identical (test of coincidence) or (ii) whether two regression 
mean functions were parallel (test of parallelism) (17).
RESULTS
In Serbia from 1991 to 2010, more than 16 000 inhabitants 
died from pancreatic cancer (approximately 9000 men and 
7000 women) (Table 1). Age-standardized mortality rates 
ranged from 5.93 to 8.57 per 100 000 in men and from 3.51 
to 5.79 per 100 000 in women. In both sexes the highest 
rates were recorded in 2010.
Pancreatic cancer mortality was continuously increasing 
since 1991 by 1.6% (95% confidence interval [CI] 1.1 to 2.0) 
yearly in men and by 2.2% (95% CI 1.7 to 2.7) yearly in wom-
en (Figure 1, Table 1). According to comparability test, pan-
creatic mortality trends in men and women were parallel 
(final selected model failed to reject parallelism, P = 0.243).
Mortality from pancreatic cancer was higher among men 
than among women in all age groups (Table 2). There 
were some sex differences in time trends by age. Among 
men, changes in mortality were small and not significant 
in younger age groups (<55 years), but in participants 55 
years and older mortality was increasing, although in the 
age groups 70-74 and 80-84 the increase was not signifi-
cant. In 65-69 years old men, the increase in mortality was 
significant only in the period from 2004 to 2010. Among 
women, changes in mortality in younger age groups (40-
44 and 45-49 years) were not significant, but in older age 
groups mortality significantly increased from 1991 onward. 
The exception were 75-79 years old women, in whom a 
non-significant decreasing trend in the period 1991 to 
2000 was followed by a significant increase from 2000 to 
2010. According to comparability test, mortality trend in 
50-54 years old men and 75-79 and 85+ years old women 
TAbLE 1. Pancreatic cancer mortality in Serbia, excluding the 
Autonomous Province of Kosovo and Metohia, in the period 
1991-2010, by sex. Number of cases, crude rate, and age 
standardized rate (ASR, per 100 000, using world standard 
population)
Men Women
Year N crude rate ASR N crude rate ASR
1991 392 10.55 7.03 246  6.34 3.50
1992 366  9.85 6.41 265  6.82 3.76
1993 335  9.00 5.93 261  6.70 3.51
1994 356  9.56 6.17 273  7.00 3.65
1995 354  9.50 6.01 307  7.87 4.10
1996 412 11.06 6.87 296  7.59 3.80
1997 396 10.68 6.64 343  8.82 4.42
1998 416 11.28 6.77 337  8.68 4.28
1999 438 11.94 7.11 344  8.86 4.28
2000 401 10.97 6.48 346  8.96 4.28
2001 445 12.20 7.04 327  8.48 4.00
2002 466 12.78 7.22 369  9.58 4.49
2003 451 12.40 6.98 404 10.51 4.88
2004 476 13.12 7.32 376  9.78 4.29
2005 518 14.32 8.07 470 12.29 5.31
2006 520 14.43 7.99 390 10.24 4.54
2007 491 13.68 7.42 475 12.52 5.13
2008 561 15.70 8.29 473 12.53 5.17
2009 546 15.34 8.19 474 12.60 5.01
2010 566 15.96 8.57 522 13.94 5.79
TAbLE 2. Joinpoint regression analysis of pancreatic cancer 
mortality in Serbia, excluding the Autonomous Province of 





average annual percent change 
(95% confidence interval [CI])
Men
40-44  3.15 + 0.4 (-3.1 to 4.0)
45-49  6.26 + 0.9 (-0.9 to 2.8)
50-54 13.03 - 0.3 (-1.3 to 0.8)
55-59 23.36 + 2.6‡ (1.4 to 3.8)
60-64 30.39 + 2.1‡ (0.7 to 3.4)
65-69† 43.00 + 2.6‡ (1.1 to 4.2)
70-74 55.71 + 1.0 (-0.1 to 2.2)
75-79 60.62 + 1.6‡ (0.7 to 2.6)
80-84 72.15 + 1.0 (-1.2 to 3.1)
85+ 55.37 + 2.6‡ (0.6 to 4.7)
All men + 1.6‡ (1.1 to 2.0)
Women
40-44  1.51 - 2.0 (-6.1 to 2.3)
45-49  3.34 + 1.0 (-2.0 to 4.0)
50-54  6.85 + 2.9‡ (0.8 to 5.0)
55-59 11.22 + 2.4‡ (0.9 to 3.8)
60-64 18.95 + 1.9‡ (0.8 to 3.0)
65-69 26.43 + 1.5‡ (0.4 to 2.5)
70-74 37.39 + 2.5‡ (1.7 to 3.3)
75-79§ 46.07 + 3.0‡ (1.0 to 5.0)
80-84 51.88 + 3.1‡ (1.4 to 4.8)
85+ 44.83 + 4.3‡ (2.6 to 5.9)
All women + 2.2‡ (1.7 to 2.7)
*Joinpoint results are not shown for the age subgroups <40, because 
there were fewer than 5 cases in any year. 
†Trend 1 (1991-2004): annual percent change (APC) (95% CI) = +0.9 
(-0.4 to 2.2); Trend 2 (2004-2010): APC (95% CI) = +6.6‡ (2.2 to 11.2). 
‡Joinpoint is significantly different from zero at alpha = 0.05. 
§Trend 1 (1991-2000): APC (95% CI) = -0.3 (-3.4 to 3.0); Trend 2 (2000-
2010): APC (95% CI) = 5.9‡ (3.1 to 8.9).
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differed significantly from mortality trends in the majority 
of other age groups (P < 0.05).
DISCUSSION
This study described pancreatic cancer mortality trends for 
Serbian population in the last two decades and found an 
increasing trend in both sexes and most age groups. Age-
standardized pancreatic cancer mortality in Serbian men of 
8.29 per 100 000 in 2008 is high compared with other Euro-
pean countries (3). The highest mortality rate in men was re-
ported in Hungary (11.56 per 100 000), followed by Armenia 
(10.81), Albania (10.70), Croatia (9.47), and Russian Federa-
tion (8.83). The highest mortality rate in women was found 
in Finland (7.14 per 100 000), Czech Republic (7.13), and 
Hungary (7.07). The lowest mortality rates were found in Cy-
prus and Turkey, both in men (3.69 and 3.72 per 100 000, re-
spectively) and women (2.43 and 2.49 per 100 000, respec-
tively). Rates for both sexes were higher in eastern Europe 
than in the European Union (18,19). In Serbian population, 
as well as in other populations (3), pancreatic cancer deaths 
rates were higher in men than in women.
Worldwide trends for both sexes in the second half of 
the 20th century varied considerably (6,19). They were in-
creasing throughout Europe (the European Union and 6 
selected eastern European countries) between the late 
1950s and the 1980s, and leveled off in the 1990s (19). In 
the USA, they steeply increased until the mid-1970, when 
they reached a peak, then gradually declined by 0.1% per 
year until 2001, after which they began to rise until 2009 
(by 0.5%) (6,20).
Pancreatic cancer mortality rates in Serbia showed an in-
creasing trend in both sexes. An increasing trend in both 
sexes was also noticed in most countries of central, eastern, 
and southern Europe (8,21). A decreasing trend, on the oth-
er hand, was found in men in Denmark, the Netherlands, 
the United Kingdom, and in Nordic countries, and a lev-
el-off was observed in France, Portugal, and Austria (8,22). 
Yearly mortality rates from 2002 to 2009 have been slightly 
rising in the USA, by 0.5% in men and by 0.4% in women (6). 
Also in Japan (23), at the end of the 1990s, pancreatic can-
cer mortality increased by 0.4% per year in women aged 65-
84, and decreased by 0.2% in men of the same age. Recent 
pancreatic mortality trends in the Netherlands, Norway, Po-
land, and Switzerland in the age group 35-64 years were fa-
vorable for men, but unfavorable for women (8).
Since diagnostic and treatment improvements in the last 
decades (24,25) have not substantially influenced the sur-
vival rate of pancreatic cancer, its mortality rate still de-
FIgURE 1. Joinpoint regression analysis of pancreatic cancer mortality in Serbia, excluding the Autonomous Province of Kosovo and 
Metohia, in the period 1991-2010, by sex. ASR (W) – age standardized rate (per 100 000, using world standard population); APC – an-
nual percent change. *The APC change is significant (two-sided P < 0.05).
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pends mainly on its incidence. International differences in 
mortality rates and temporal trends suggest that etiology 
of pancreatic cancer is influenced by environmental fac-
tors, especially smoking, but also by nutritional and dietary 
factors, obesity, alcohol use, and diabetes mellitus (26-29).
The strongest environmental risk factor for pancreatic can-
cer is smoking. For example, the relative risk of pancreat-
ic cancer in smokers compared to non-smokers was 2.0 
(29,30) and the proportion of pancreatic cancer attribut-
able to cigarette smoking in US African-Americans was 
29% and 26% in Caucasians (31). As for other tobacco-re-
lated malignant tumors, international disparities in mortal-
ity trends most likely reflect different rates of tobacco use 
(30-34). Tobacco exposure in Serbia is high. The percentage 
of male and female smokers in Belgrade in 1976 and 1977 
was 49% and 25%, respectively; in 1988 and 1989, 51% and 
37% (35), and in 2000, 48% and 38% (32). The antismoking 
campaign, which was intensified from 2000, contributed 
to a decrease in the number of smokers (38% of men and 
30% of women in 2006) (36). Serbian joining of the World 
Health Organization Convention on Tobacco Control in 
June 2006 is expected to bring about a further reduction 
in the number of smokers.
However, there are also other important risk factors for 
pancreatic cancer; according to the data for 2006, 3.4% of 
the adult population of Serbia consumed alcohol on a dai-
ly basis, which is an increase of 0.1% compared with 2000 
(3.3%) (36). As in many other countries, the frequency of 
obesity and diabetes in Serbia has been increasing, and 
the increase is estimated to continue (37,38). In 2000 as in 
2006, one in two adults was overweight, 18.3% were obese, 
and 36.2% were pre-obese, and the number of overweight 
and obese 7-19 years old children increased from 12.6% to 
18.0% (36). In 2006, about 6.8% of adults in Serbia had dia-
betes mellitus (6.2% of men and 7.5% of women), which 
is significantly higher than 4.8% in 2000 (4.5% of men and 
5.0% of women) (39,40). Taking all this into account, it 
seems very difficult to predict the future pancreatic cancer 
mortality trend, although moderate and insignificant mor-
tality changes in younger age groups are promising.
A limitation of the present study is related to the reliability 
and validity of death certificates. The World Health Orga-
nization assessed the quality of Serbian data on the cause 
of death as moderate (41). Besides that, pancreatic cancer 
is difficult to diagnose and the increasing mortality trends 
may be related to greater diagnostic accuracy (20). It can 
be assumed that diagnostics of pancreatic cancer was 
worse during the first half of the observed period (from 
1991 to 2000) than during the second half, because of the 
war and economic crisis in the country. The proportion of 
cases with uncertain death cause (revision 9 codes 780-
799 and revision 10 codes R00-R99) in the observed peri-
od was on average 6.8%, with a non-significant decreasing 
trend (P = 0.137). In the majority of developed countries, 
the quality of death certification is better than in Serbia. 
For example, the proportion of uncertain causes of death 
in Nordic countries is 1% (42) and 5% in China (43). We 
have no data on changes in the autopsy rate during the 
studied period, which could influence the mortality cod-
ing. Registration of autopsies in Serbia began in 2006. From 
2006 to 2010, autopsy was performed in 2.1% of all deaths 
and 2.6% of pancreatic cancers diagnosed at autopsy were 
missing on the death certificate. We also have no data on 
possible changes in survival of pancreatic cancer patients, 
but it is not probable that survival deteriorated during the 
observed period since the treatment progress has been 
negligible (44-46). During the study period, there was a 
change from ICD9 to ICD10, but it seems not to have had 
an effect on the overall rates of pancreatic cancer. There are 
no data on pancreatic cancer incidence for the entire Ser-
bia without Kosovo and Metohia (Central Serbia and Vojvo-
dina). For the period 1999 to 2010, there are only data for 
Central Serbia, showing a non-significant increasing trend 
of age-standardized pancreatic cancer incidence in both 
sexes (P = 0.338 in men and P = 0.679 in women) (47).
Serbia is among the countries with the highest pancreatic 
cancer mortality in the world. An increasing mortality trend 
was present in both sexes and in most age groups. Pancre-
atic cancer is one of the leading causes of cancer death 
in Serbia and therefore further effort should be made to 
clarify its etiology and risk factors.
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